Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Inc has announced that its subsidiary Mylan Pharmaceuticals Inc has received final approval from the FDA for its abbreviated new drug application for risperidone tablets USP, 0.25mg, 0.5mg, 1mg, 2mg, 3mg and 4mg.
Subscribe to our email newsletter
Risperidone tablets, used to treat schizophrenia and bipolar disorder, are the generic version of Janssen’s Risperdal tablets. Mylan will ship the product shortly.
Currently, the company has 109 abbreviated new drug applications pending FDA approval, 22 of which are potential first-to-file opportunities.